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Abstract
Purpose Rates of progression of endometrial hyperplasia (EH) to endometrial cancer (EC) are highly variable. Among sev-
eral prognostic markers, PTEN has been recommended by ESMO–ESGO–ESTRO to identify premalignant EH. However, 
its prognostic accuracy is unclear. Thus, we aimed to assess: (1) the association between PTEN loss in EH and risk of cancer, 
and (2) the prognostic accuracy of PTEN immunohistochemistry in EH.
Methods Electronic databases were searched from their inception to June 2018. All studies assessing PTEN immunohisto-
chemistry in EH and the presence of EC on subsequent hysterectomy were included. Odds ratio (OR), sensitivity, specificity, 
positive and negative predictive value (PPV and NPV), positive and negative likelihood ratio (LR + and LR−) and area under 
the curve (AUC) on SROC curves were calculated with subgroup analysis (short/long-term; atypical/non-atypical EH).
Results Nine retrospective studies assessing 933 EH were included. PTEN loss in EH was significantly associated with 
increased risk of EC (OR = 3.32, p = 0.001). The association was significant only on the short term ( < 1 year) (OR = 3.45, 
p = 0.002) and in atypical EH (OR = 1.89, p = 0.01). For overall analysis and short-term/atypical EH subgroup the prognostic 
accuracy was low, with sensitivity = 0.58 and 0.68, specificity = 0.60 and 0.48, VPp = 0.41 and 0.54, VPN = 0.75 and 0.63, 
LR +  = 1.80 and 1.37, LR − =  0.62 and 0.56, AUC = 0.687 and 0.721, respectively.
Conclusion PTEN loss in EH is a risk factor for EC, but is not reliable in predicting the risk of EC. In atypical EH, PTEN 
loss is associated with a risk of concurrent EC of over 50%. This information might integrate the patients’ informed consent 
for the choice of treatment (conservative/hysterectomy), especially in borderline cases. In conservative approach, PTEN 
loss might suggest closer follow-up.
Keywords EIN · Endometrial intraepithelial neoplasia · Endometrioid adenocarcinoma · Immunohistochemical · 
Prognosis · Tumor suppressor protein phosphatase · Tensin homolog
Introduction
Endometrial hyperplasia (EH) is an irregular proliferation of 
endometrial glands [1]. EH is involved in the development 
of endometrial cancer (EC) of endometrioid type [2], which 
is the most common gynecologic malignancy in the Western 
World [3]. Since EH can be a precancerous lesion as well 
as a polyclonal proliferation caused by unopposed action of 
estrogens [4, 5], its malignant potential is highly variable, 
with rates of progression to EC ranging from less than 1% 
to over 40% [6–9]. To choose an appropriate treatment a dif-
ferential diagnosis between benign and premalignant EH is 
needed. In particular, benign EH requires only observation 
or progestins when symptomatic, while premalignant EH 
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requires hysterectomy or progestins for conservative approach 
in selected cases [4, 10].
The World Health Organization (WHO) 2014 classifica-
tion system differentiates atypical EH (premalignant) from EH 
without atypia (benign) based on the presence of cytologic 
atypia [1, 11]. Previous WHO systems had also considered 
the complexity of glandular architecture for EH classification, 
although its impact on the malignant potential was not well 
defined [5, 6, 11].
However, WHO system does not perfectly reflect the risk 
of progression to cancer. In fact, only a minority of atypical 
EH progress to EC (8.2–27.5%), while a little percentage of 
EH without atypia still progress (1.2–4.6%) [8]. Furthermore, 
WHO criteria have shown problems of reproducibility, with 
endometrial specimens often showing ambiguous features [5, 
12]. The endometrial intraepithelial neoplasia (EIN) system is 
an alternative classification system based on nuclei diameters, 
glandular perimeter and gland to stroma ratio [5, 9]. These 
parameters can be assessed objectively through a computer-
ized analysis calculating a prognostic score (D-score) and 
providing a reliable risk stratification [5, 9, 11]. Nonetheless, 
D-score was not widely applicable in the common practice due 
to the cost of a morphometry workstation [5, 13].
For these reasons, there has been great interest in the litera-
ture about cheaper prognostic markers in EH [11]. The tumor 
suppressor protein phosphatase and tensin homolog (PTEN) 
has probably been the most studied marker, since PTEN gene 
is the most commonly mutated in endometrial carcinogenesis 
[14].
In the 2016 ESMO-ESGO-ESTRO Consensus Conference 
on Endometrial Cancer, the immunohistochemical assessment 
of PTEN has been recommended to recognize premalignant 
EH, which often show a loss of expression of the protein [15]. 
Nonetheless, in our previous study we found that the accuracy 
of PTEN immunohistochemistry was low [16]. Such study 
was based on the histologic classification of EH into benign 
or premalignant. However, despite being the gold standard, 
histology might not reflect the actual rates of progression to 
EC, as discussed above.
Thus, the aim of this study was to analyse the prognostic 
value of immunohistochemical assessment of PTEN expres-
sion in EH, by assessing the actual risk of progression to can-
cer. In this regard, we analysed first the association between 
PTEN loss and risk of progression to EC, and then the prog-
nostic accuracy of PTEN assessment in predicting progression 
to EC.
Materials and methods
Study protocol
This study was performed following a recommended pro-
tocol for systematic review and meta-analysis. The study 
protocol defining methods for collection, extraction and 
analysis of data, including subgroups analyses, was designed 
a priori. All review stages were conducted independently 
by two reviewers (AR, AT), who independently assessed 
electronic search, eligibility of the studies, inclusion criteria, 
risk of bias, data extraction and data analysis. Disagreements 
were resolved by discussing with a third reviewer (GS).
The study was reported following the Preferred Reporting 
Item for Systematic Reviews and Meta-analyses (PRISMA) 
statement [17].
Search strategy
Using MEDLINE, EMBASE, Web of Sciences, Scopus, 
ClinicalTrial.gov, OVID, Cochrane Library and Google 
Scholar as electronic databases, the relevant articles were 
searched from database inception to June 2018, through 
a combination of the following words and all their syno-
nyms found on Medical SubHeading (MeSH) vocabulary: 
“endometrial hyperplasia”; “endometrial intraepithelial 
neoplasia”; “EIN”; “cancer”; “precancer”; “premalignant”; 
“precursor”; “PTEN”; “phosphatase and tensin homolog”; 
“marker”; “biomarker”; “prognosis”; “progression”; “risk”; 
“immunohistochemistry”; “immunohistochemical”. Review 
of articles also included the abstracts of all references 
retrieved from the search.
Study selection
We included all peer-reviewed, retrospective or prospective 
studies assessing the association between immunohisto-
chemical expression of PTEN in EH on endometrial biopsy 
and the presence of EC on a subsequent hysterectomy.
Exclusion criteria were:
– data regarding PTEN expression not extractable;
– case reports and reviews;
– overlapping patient data with a study already included;
Risk of bias assessment
The risk of bias was assessed according to the revised Qual-
ity Assessment of Diagnostic Accuracy Studies (QUA-
DAS-2) [18]. Four domains related to risk of bias were 
assessed in each study: (1) patient selection (low risk if the 
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patients were consecutive or randomly selected from a con-
secutive series), (2) index test (low risk if the assessment 
of PTEN expression was made according to complete and 
clearly defined criteria), (3) reference test (low risk if the 
diagnosis of endometrial cancer was not affected by biases, 
such as cancer on biopsy not confirmed at hysterectomy), 
(4) flow and timing (low risk if the latency time between EH 
biopsy and cancer diagnosis did not introduce a bias, such 
as confusion between coexistent and subsequent cancer). 
Review authors’ judgments were categorized as “low risk,” 
“high risk” or “unclear risk of bias.” Concerns about appli-
cability of the domains 1, 2 and 3 (if methods of the included 
do not suit the aim of our review, regardless of their correct-
ness) were also assessed and categorized as “low concerns,” 
“high concerns” or “unclear concerns” about applicability.
Data extraction
Data from each eligible study were extracted without modifi-
cation of original data. Two by two contingency tables were 
prepared for each study, reporting two dichotomous qualita-
tive variables:
– PTEN expression on the index endometrial biopsy 
(“loss” or “presence”);
– subsequent diagnosis of EC at histologic examination of 
endometrial specimen (“cancer” or “no cancer”).
If discrepancies between values reported in the text and 
the tables were found, values from tables were used for the 
analysis.
In the analysis of prognostic accuracy, PTEN expression 
on the index endometrial biopsy was considered the index 
test, and subsequent diagnosis of EC was considered the 
reference test. The combination “PTEN loss” with “cancer” 
was considered as true positive, “PTEN presence” with “no 
cancer” as true negative, “PTEN presence” with “cancer” 
as false negative, “PTEN loss” with “no cancer” as false 
positive.
The association of PTEN loss with cancer and the prog-
nostic accuracy of PTEN immunohistochemistry for the risk 
of cancer were the two primary outcomes of our study.
Moreover, data were also subdivided according to two 
different criteria, defined a priori:
– on the basis of the latency time between index and refer-
ence test, the studies were subdivided into two “latency 
time subgroups”: “short term subgroup” (mean latency 
time < 1 year) and “long term subgroup” (mean latency 
time ≥ 1 year); in fact, several authors highlighted that 
in case of a latency time < 1 year the cancer should be 
considered as “concurrent” rather than “subsequent”, 
because of the typically slow growth of EC [9, 19];
– on the basis on the WHO classification, EH was subdi-
vided into two “WHO subgroups”: “EH without atypia 
subgroup” and “atypical EH subgroup”.
Moreover, data were subdivided into four combined sub-
groups, based on the combination of latency time and WHO 
classification: (1) short term and EH without atypia; (2) 
short term and atypical EH; (3) long term and EH without 
atypia; (4) long term and atypical EH.
Data analysis
PTEN loss and risk of cancer
The association between PTEN loss and risk of cancer was 
assessed using odds ratio (OR); a p value < 0.05 indicated 
a significant impact on the risk. OR was calculated for each 
study and as pooled estimate and reported graphically on 
forest plot, with 95% confidence interval (CI). OR was also 
assessed separately in the different subgroups, and results 
were compared using χ2 test with significant p value < 0.05.
Statistical heterogeneity among studies was assessed 
using the inconsistency index I2: heterogeneity was consid-
ered insignificant for I2 < 25%, low for I2 < 50%, moderate 
for I2 < 75% and high for I2 ≥ 75%. In case of I2 < 50%, the 
fixed-effect model of Mantel–Haenszel was used; other-
wise, the random effect model of DerSimonian–Laird was 
adopted.
Pre- and post-test probabilities of cancer were reported 
graphically using a Fagan’s nomogram.
Review manager 5.3 (Copenhagen: The Nordic Cochrane 
Centre, Cochrane Collaboration, 2014) was used for the 
analysis.
Prognostic accuracy
The prognostic accuracy was assessed as sensitivity, speci-
ficity, positive predictive value (PPV), negative predictive 
value (NPP), positive likelihood ratio (LR + ) and nega-
tive likelihood ratio (LR−). The prognostic usefulness was 
assessed as “area under the curve” (AUC) on summary 
receiver operating characteristic (SROC) curves, and was 
considered absent for AUC ≤ 0.5, low for 0.5 < AUC ≤ 0.75, 
moderate for 0.75 < AUC ≤ 0.9, high for 0.9 < AUC < 0.97, 
very high for AUC ≥ 0.97.
Sensitivity, specificity, PPV, NPV, LR + and LR− were 
assessed for each study and as pooled estimate and reported 
graphically on forest plots, with 95% confidence interval 
(CI).
The random effect model of DerSimonian–Laird was 
planned a priori, since an actual heterogeneity is expected 
for meta-analyses of prognostic accuracy [20].
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In the subgroup analysis, the prognostic accuracy was 
assessed only for combined subgroups, to contextualize the 
clinical usefulness of PTEN immunohistochemistry, and 
only in those showing a significant OR. For the subgroups 
in which OR was found non-significant, the possibility of a 
prognostic usefulness was excluded a priori.
Meta-DiSc version 1.4 (Clinical Biostatistics Unit, 
Ramon y Cajal Hospital, Madrid, Spain) was used for the 
analysis.
Results
Study selection
Nine retrospective studies [19, 21–28] with a total sample 
size of 933 EH were included. The process of study selection 
is reported in detail in Fig. 1.
Characteristics of the studies
Six studies had a retrospective cohort design, while three 
were case–control studies. Five studies adopted WHO clas-
sification system; two studies categorized EH specimens 
based on a computerized morphometric analysis (D-score); 
one study used the subjective EIN classification; the 
Fig. 1  Flow diagram of studies 
identified in the systematic 
review [Prisma template 
(preferred reporting item for 
systematic reviews and meta-
analyses)]
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remaining study adopted all three systems. Fifty-two point 
three percent of EH were classified as benign and 47.7% as 
precancerous.
Eight of nine studies dichotomized PTEN expression 
into positive and negative in the results; the remaining one 
graded PTEN expression as “low”, “intermediate” and 
“high”, where “low” denoted negative staining [27].
PTEN expression was assessed in EH glands, while the 
surrounding endometrial stroma was used as internal posi-
tive control.
PTEN loss was observed in 173 of 298 (58.1%) EH with 
progression to EC and in 252 of 635 (39.7%) EH without 
progression to EC.
Details are shown in Table 1.
Risk of bias assessment
Results of risk of bias assessment are shown in Fig. 2.
For the “patient selection” domain, three studies were 
categorized at low risk of bias, due to the inclusion of con-
secutive patients; the others were categorized at unclear risk. 
Concerns about the applicability of this domain were con-
sidered unclear for one study, since it assessed only atypical 
EH with metaplastic surface changes.
For the “index test” domain, three studies were catego-
rized at low risk of bias, because they specified in detail the 
criteria to define PTEN loss; the others were considered at 
unclear risk.
For the “reference test” domain, one study was consid-
ered at unclear risk, since some diagnoses of EC were made 
at histologic examination of dilatation and curettage speci-
mens, and it is not specified if the diagnosis was confirmed 
on hysterectomy specimen. For the other eight studies, no 
particular risks of bias were highlighted, thus all studies 
were considered at low risk.
For the “flow and timing” domain, three studies were cat-
egorized at unclear risk of bias: one of them did not clearly 
differentiate the results based on the latency times ( < or 
> 1 year), the other two did not specify the latency time 
between index and reference test (Table 1). The remaining 
studies were considered at low risk.
No study was considered at high risk of bias. No further 
applicability concerns were found.
PTEN loss and risk of cancer
Overall results
PTEN loss in EH was significantly associated with increased 
risk of EC, with an overall OR of 3.32 (95% CI 1.59–6.97, 
p = 0.001) and high heterogeneity among studies (I2 = 75%). 
Results of OR analysis are reported graphically in Fig. 3a.
Latency time subgroups
In the subgroup analysis based on latency time, five studies 
assessing 396 EH were included in the short-term subgroup, 
and four studies assessing 537 EH were included in the long-
term subgroup. In the short-term subgroup, the association 
of PTEN loss with EC risk was stronger, with an OR of 3.45 
(95% CI 1.59–7.50, p = 0.002) and moderate heterogeneity 
(I2 = 60%). On the other hand, in the long latency subgroup 
the association was weaker and not statistically significant, 
with an OR of 3.37 (95% CI 0.70–16.33, p = 0.13) and high 
heterogeneity (I2 = 78%) (Fig. 3a).
WHO subgroups
The subgroup analysis based on WHO classification 
included 260 EH without atypia and 199 atypical EH. The 
“EH without atypia subgroup” showed no significant asso-
ciation between PTEN loss and EC risk, with an OR of 0.75 
(95% CI 0.44–1.29, p = 0.30 and insignificant heterogeneity 
(I2 = 11%). For the “atypical EH subgroup”, the association 
was significant, with an OR of 1.89 (95% CI 1.16–3.06, 
p = 0.01) and low heterogeneity (I2 = 38%) (Fig. 3b).
Combined subgroups
Among the four combined subgroups, only the one consider-
ing “short term” and “atypical EH” (subgroup 2; N = 208), 
showed significant association, with an OR of 2.51 (95% CI 
1.36–4.61, p = 0.003) and with low heterogeneity (I2 = 46%) 
(Fig. 3c).
Prognostic accuracy
Overall results
Pooled sensitivity and specificity of PTEN loss in predict-
ing EC were 0.58 (95% CI 0.52–0.64) and 0.60 (95% CI 
0.56–0.64), respectively. Pooled PPV and NPV were 0.41 
(95% CI 0.36–0.46) and 0.75 (95% CI 0.71–0.79), respec-
tively. Pooled LR + and LR− were 1.80 (95% CI 1.26–2.56) 
and 0.62 (95% CI 0.45–0.86), respectively. The heteroge-
neity was moderate for sensitivity (I2 = 67.8%), high for 
specificity (I2 = 89.3%), PPV (I2 = 82.8%), NPV (I2 = 91.1) 
and LR + (I2 = 83%), and moderate for LR− (I2 = 66.3%) 
(Fig. 4a). The SROC curves analysis demonstrated low 
overall prognostic accuracy with an AUC of 0.687 (Fig. 4b).
Short term/atypical EH subgroup
In the combined subgroup, pooled estimates showed sensi-
tivity of 0.68 (95% CI 0.58–0.77), specificity of 0.48 (95% 
CI 0.39–0.59), PPV of 0.54 (95% CI 0.45–0.63), NPV of 
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0.63 (95% CI 0.52–0.73), LR + of 1.37 (95% CI 0.89–2.12) 
and LR− of 0.56 (95% CI 0.41–0.77). The heterogeneity 
was high for specificity (I2 = 86.5) and PPV (I2 = 87.5%), 
moderate for LR + (I2 = 56.4%), insignificant for sensitiv-
ity (I2 = 15.4%), and absent for NPV and LR− (I2 = 0%) 
(Fig. 5a). The SROC curves analysis demonstrated low 
overall prognostic accuracy with an AUC of 0.721 (Fig. 5b).
Discussion
Main findings and interpretations
Overall results
According to our results, the loss of PTEN expression in EH 
is significantly associated with increased risk of EC. These 
findings might be expected, since PTEN mutation is known 
to be involved in endometrial carcinogenesis. Among the 
four molecular categories of EC identified by the Cancer 
Genome Atlas Research Network (‘ultramutated’, ‘hyper-
mutated’ and ‘copy number low’, which are predominantly 
endometrioid, and ‘copy number high’, most of which are 
serous), PTEN mutations were found in 94%, 88%, 77% 
and 15%, respectively [14]. Furthermore, several studies 
Fig. 2  a Assessment of risk of bias. Summary of risk of bias for each study; Plus sign: low risk of bias; minus sign: high risk of bias; question 
mark: unclear risk of bias. b Risk of bias graph about each risk of bias item presented as percentages across all included studies
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reported a higher rate of PTEN loss in EC compared to EH 
[29–31], suggesting a prognostic significance of PTEN. In 
spite of this, we found a low prognostic usefulness of PTEN 
assessment in predicting EC, with sensitivity and specificity 
of 0.58 and 0.60, respectively, considerably lower than the 
values reported by Baak et al. for WHO system (0.67 and 
0.76, respectively) [9]. Our results confirm those of our pre-
vious study [16], indicating that PTEN evaluation is not a 
Fig. 3  Forest plot of individual studies and pooled odds ratio for risk 
of cancer, with subgroups analyses based on the latency time between 
index biopsy and cancer diagnosis (a) and the presence of cytologic 
atypia in the index biopsy (b). In (c) the analysis of the selected com-
bined subgroup of ‘short term’ and ‘atypical hyperplasia’ is reported
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Fig. 4  Overall analysis for prognostic accuracy of PTEN immunohistochemical status. Forest plots of individual studies and pooled sensitivity, 
specificity, positive and negative predictive value, positive and negative likelihood ratio (a), with SROC curves (b)
1520 Archives of Gynecology and Obstetrics (2019) 299:1511–1524
1 3
reliable tool in differentiating benign and premalignant EH. 
Thus, it appears inadequate to replace WHO histomorpho-
logic criteria in selecting patients who need to be treated. 
For this reason, we do not recommend the indiscriminate use 
of PTEN immunohistochemistry in the diagnostic algorithm 
of EH. However, it should be remarked that PTEN is not 
the only molecule involved in endometrial carcinogenesis. 
In two included articles, mismatch repair proteins appeared 
associated with the risk of EC more strongly than PTEN [21, 
28]. One of these papers also suggested to use a combina-
tion of several markers to better stratify the risk [28]. In this 
regard, many other proteins, such as PAX2, Bcl-2, β-catenin 
Fig. 5  Analysis of prognostic accuracy of PTEN immunohistochemi-
cal status in the selected subgroup of atypical hyperplasia with a 
short follow-up ( < 1  year). Forest plots of individual studies and 
pooled sensitivity, specificity, positive and negative predictive value, 
positive and negative likelihood ratio (a), with SROC curves (b)
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and ARID1A [32–36], might have a role in improving the 
risk stratification in EH. Further studies are necessary in 
this field.
Latency time and WHO criteria‑weighted results
We found that the association of PTEN loss with risk of EC 
was significant only when a short follow-up ( < 1 year) was 
considered. Several authors pointed out that an EC diag-
nosed within 1 year after EH diagnosis should be considered 
as already present at the time of EH biopsy, due to the typi-
cally slow growth of EC [9, 19]. Thus, our results suggest 
that PTEN loss in EH predicts the presence of a coexistent 
EC rather than the progression of EH to EC. The reason 
could be that PTEN status does not affect the responsive-
ness of EH and EC to progestins [37], resulting in similar 
outcomes between PTEN-null and PTEN-positive specimens 
on the long term in treated patients.
In the analysis of WHO subgroups, the association of 
PTEN loss with cancer risk was significant only in atypical 
EH, while it was absent in EH without atypia. A possible 
explanation might be that the loss of PTEN expression alone 
is not enough to activate malignant transformation. In fact, 
Mutter et al. showed that endometrial glands with loss of 
PTEN at immunohistochemistry, but normal histomorphol-
ogy, tended to spontaneously regress in most cases [37]. On 
the other hand, atypical EH have several genetic alterations 
[38], which might determine the progression to EC when 
combined with PTEN loss. Moreover, our results are also 
in accordance with Pavlakis et al., who reported that the 
combination of cytologic atypia and PTEN loss predicted 
coexistent cancer better than cytologic atypia alone [24].
Given these observations, the question is how PTEN 
evaluation may influence the management of patients with 
atypical EH, with regard to the risk of concurrent cancer. 
Even in this subset of patients (short term and atypical EH), 
the prognostic accuracy was low (AUC = 0.721), with sub-
optimal sensitivity (0.68) and very low specificity (0.48). 
Instead, the identification of women at risk of cancer would 
require a good sensitivity, to avoid progression to cancer 
in untreated patients. At the same time, a high specificity 
would also be needed to avoid a severe overtreatment such as 
hysterectomy. Thus, even for atypical EH, PTEN evaluation 
can be indiscriminately used in the diagnostic-therapeutic 
algorithm.
Despite the low prognostic accuracy, we found a PPV of 
0.54 (Fig. 5), indicating a risk of concurrent EC of over 50% 
(Fig. 6). Since EC conservatively treated has shown lower 
regression and higher recurrence rates compared to atypical 
EH [39], it may be crucial to obtain this information in the 
decision-making between conservative treatment or hyster-
ectomy, especially in borderline cases, such as age older than 
40 years, pluriparity, wish to get pregnant not in the short 
term, low couple fertility potential. In these conditions, a 
finding of PTEN loss may integrate the informed consent, 
making the patient aware that it is more likely that a can-
cer is already present than not. However, if a conservative 
approach is still chosen, PTEN loss may indicate the need 
for a closer and more careful follow-up.
Strength and limitations
To the best of our knowledge, this is the first meta-analysis 
assessing PTEN as a prognostic marker of cancer progres-
sion in EH. Since data in this field are based only on retro-
spective studies with unclear results, this meta-analysis may 
considerably increase the strength of evidence.
However, the retrospective design of the studies may 
itself limit the significance of the results found.
The first limitation for our findings may be the high het-
erogeneity among the included studies, especially about the 
sample size. In fact, the greatest study included 308 EH, 
while the smaller one only 18. Since the number of included 
studies is not large (N = 9), such a limitation might affect in 
particular the subgroups analysis. Differences in the patient 
management may also be a limitation, as different treatments 
may lead to different outcomes [40–43]. Power calculation 
was not performed given the study design of our review.
The inter-observer variability in the interpretation of 
PTEN immunostaining might constitute a minor limitation 
for our study. In fact, Allison et al. pointed out that the sev-
eral authors adopted different criteria to define PTEN loss 
[44]. However, even in the absence of a validated method 
for grading PTEN expression, Garg et al. showed that a 
solely qualitative scoring of PTEN immunohistochemistry 
in EC into positive, negative and heterogeneous, was highly 
reproducible [45]. In our previous study, we showed that a 
subjective interpretation of PTEN immunohistochemistry in 
EH was even more accurate than an objective, quantitative 
scoring [46].
Conclusion
The loss of PTEN immunohistochemical expression in EH 
is significantly associated with increased overall risk of EC. 
However, its prognostic accuracy is too low to replace histo-
morphologic criteria.
In the subset of patients with atypical EH, PTEN loss 
is associated with a risk of coexistent cancer of over 50%. 
This information might integrate the patients’ informed 
consent for the choice of treatment (conservative or hys-
terectomy), and might be crucial in borderline cases, such 
as age older than 40 years, pluriparity, wish to get pregnant 
not in the short term, low couple fertility potential. Finally, 
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if a conservative approach is still chosen, PTEN loss might 
indicate the need for a closer and more careful follow-up.
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